Accolate captures 3.4% of new asthma controller scripts; Zeneca Zoladex sales gain 57%.
Executive Summary
ZENECA ACCOLATE GARNERS 3.4% OF ASTHMA CONTROLLER NEW RXs BY JANUARY, three months after its October launch, according to Scott Levin's Rx Watch. In January, "Accolate captured nearly 4% of the new retail dollars," Scott-Levin stated. "Its share has steadily increased since it was launched." Scott-Levin calculated that Accolate produced 41,000 new prescriptions in January, generating $2.2 mil. retail dollars. Primary care physicians wrote 50% of January Accolate prescriptions, followed by pulmonary disease specialists, with 22% of scripts, and allergists, with 16%. The agent's share among pulmonary and allergy specialists was "considerably higher than its 3.4% share overall," Scott-Levin commented.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth